Fortress Biotech Reports Sharply Reduced 2025 Net Loss and Major Asset Monetization, Including $205M PRV Sale

summarizeSummary

Fortress Biotech reported a substantial reduction in its 2025 net loss and highlighted significant asset monetization events, including a $205 million PRV sale and multiple subsidiary acquisitions, which have strengthened its financial position.

check_boxKey Events

• Significant Reduction in Net Loss

  Consolidated net loss attributable to common stockholders for the full year ended December 31, 2025, was $(1.9) million, a substantial improvement from $(55.9) million in 2024.

• $205 Million PRV Sale by Subsidiary

  Fortress's majority-owned subsidiary, Cyprium Therapeutics, closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million in March 2026, following the FDA approval of ZYCUBO®.

• Fortress to Receive Substantial Proceeds from PRV Sale

  Fortress expects to receive an aggregate of at least $100 million from Cyprium through potential future dividends and intercompany agreements related to the PRV sale.

• Oaktree Loan Prepayment

  Fortress made aggregate prepayments on its loan with Oaktree, reducing the outstanding principal balance to $15.0 million, partially funded by the PRV sale proceeds.

auto_awesomeAnalysis

Fortress Biotech's full-year 2025 financial results show a dramatic improvement, with the net loss attributable to common stockholders shrinking from $(55.9) million in 2024 to just $(1.9) million. This significant financial turnaround is bolstered by successful asset monetization strategies. The sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its subsidiary Cyprium Therapeutics for $205 million, previously disclosed on March 30, 2026, is a major cash infusion, with Fortress expecting to receive at least $100 million. This capital has already enabled a substantial prepayment on the Oaktree loan, reducing the outstanding balance to $15.0 million, significantly strengthening the balance sheet. Additionally, the acquisitions of Checkpoint Therapeutics and Avenue Therapeutics' subsidiary Baergic, along with the Crystalys Therapeutics financing, establish long-term royalty streams and upfront payments, validating Fortress's strategy of building diversified revenue streams and creating shareholder value.